Alnylam Pharmaceuticals (ALNY) Competitors $291.68 -0.18 (-0.06%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. GILD, VRTX, REGN, BIIB, UTHR, NBIX, INCY, BMRN, EXEL, and EXASShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exelixis Exact Sciences Gilead Sciences (NASDAQ:GILD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment. Does the media favor GILD or ALNY? In the previous week, Gilead Sciences had 24 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 45 mentions for Gilead Sciences and 21 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.34 beat Gilead Sciences' score of 1.29 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 36 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Alnylam Pharmaceuticals 15 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in GILD or ALNY? 83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, GILD or ALNY? Gilead Sciences has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Do analysts rate GILD or ALNY? Gilead Sciences currently has a consensus target price of $110.55, indicating a potential upside of 1.32%. Alnylam Pharmaceuticals has a consensus target price of $319.17, indicating a potential upside of 9.42%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 9 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.78Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Which has preferable valuation and earnings, GILD or ALNY? Gilead Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$28.74B4.72$480M$4.7522.97Alnylam Pharmaceuticals$2.35B16.20-$278.16M-$2.09-139.56 Does the MarketBeat Community favor GILD or ALNY? Gilead Sciences received 1318 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. Likewise, 76.86% of users gave Gilead Sciences an outperform vote while only 76.32% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGilead SciencesOutperform Votes248576.86% Underperform Votes74823.14% Alnylam PharmaceuticalsOutperform Votes116776.32% Underperform Votes36223.68% Is GILD or ALNY more profitable? Gilead Sciences has a net margin of 1.67% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Gilead Sciences' return on equity of 31.63% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences1.67% 31.63% 10.38% Alnylam Pharmaceuticals -12.37%N/A -6.83% SummaryGilead Sciences beats Alnylam Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.03B$6.55B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-134.419.1426.8320.05Price / Sales16.20257.54394.48119.55Price / CashN/A65.8538.2534.62Price / Book560.926.546.874.61Net Income-$278.16M$143.51M$3.22B$248.19M7 Day Performance9.30%4.66%5.65%2.88%1 Month Performance24.35%10.63%13.54%15.40%1 Year Performance94.14%-1.05%18.16%7.68% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals3.5996 of 5 stars$291.68-0.1%$319.17+9.4%+94.1%$38.03B$2.35B-134.412,000Positive NewsGILDGilead Sciences4.6931 of 5 stars$103.82+7.1%$110.55+6.5%+60.7%$129.27B$28.74B280.5917,000Positive NewsOptions VolumeVRTXVertex Pharmaceuticals4.6606 of 5 stars$439.37+3.4%$515.04+17.2%+0.3%$112.83B$11.10B-199.714,800Positive NewsREGNRegeneron Pharmaceuticals4.8202 of 5 stars$575.63+9.1%$892.60+55.1%-37.7%$62.93B$14.09B15.0411,900Trending NewsDividend AnnouncementHigh Trading VolumeBIIBBiogen4.9169 of 5 stars$124.40+5.3%$191.30+53.8%-43.6%$18.23B$9.82B11.128,720Positive NewsAnalyst RevisionUTHRUnited Therapeutics4.9819 of 5 stars$310.80+3.1%$392.00+26.1%+12.7%$14.02B$2.99B13.65980NBIXNeurocrine Biosciences4.9305 of 5 stars$120.43+4.1%$162.00+34.5%-13.2%$11.92B$2.41B36.601,200Positive NewsINCYIncyte4.8942 of 5 stars$60.85+3.2%$73.53+20.8%+14.2%$11.78B$4.41B225.382,320Positive NewsBMRNBioMarin Pharmaceutical4.9841 of 5 stars$61.37+4.3%$93.45+52.3%-22.2%$11.77B$2.95B27.903,080Positive NewsInsider TradeEXELExelixis4.2648 of 5 stars$36.98+2.2%$37.59+1.6%+110.6%$10.19B$2.17B20.891,220Positive NewsEXASExact Sciences4.3503 of 5 stars$53.40+3.4%$70.90+32.8%+13.4%$10.07B$2.83B-9.596,400Positive News Related Companies and Tools Related Companies Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Exact Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
